Circulating tumor cells in colorectal cancer: Past, present, and future challenges

Current Treatment Options in Oncology

Volumn 11, Issue 1-2, 2010, Pages 1-13

  Negin, Benjamin P ^a   Cohen, Steven J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL COUNT; CELL ISOLATION; CELL MANIPULATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOMAGNETIC SEPARATION; METASTASIS; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

CELL SEPARATION; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; IMMUNOMAGNETIC SEPARATION; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 75949111131     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-010-0115-3     Document Type: Review

References (48)

1. A Jemal, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387
2. HS Hochster, et al. 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 21 3523 3529 10.1200/JCO.2007.15.4138 18640933
3. HK Sanoff, et al. 2008 Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 J Clin Oncol 26 35 5721 5727 10.1200/JCO.2008.17.7147 19001325
4. C Tournigand, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 229 237 10.1200/JCO.2004.05.113 14657227
5. E Van Cutsem, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 1408 1417 10.1056/NEJMoa0805019 19339720
6. RG Amado, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 1626 1634 10.1200/JCO.2007.14.7116 18316791
7. Van Cutsem E, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol, 2008, 26(May 20 suppl; abstr 2)
8. Falcone A, et al.: FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O. group. J Clin Oncol, 2008, 26(May 20 suppl; abstr 4031)
9. Ashworth TR: Aust Med J 1869, 14:146
10. TJ Pelkey HF Frierson Jr DE Bruns 1996 Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors Clin Chem 42 9 1369 1381 8787692
11. E Racila, et al. 1998 Detection and characterization of carcinoma cells in the blood Proc Natl Acad Sci USA 95 8 4589 4594 10.1073/pnas.95.8.4589 9539782
12. PJ Koelink, et al. 2009 Circulating cell death products predict clinical outcome of colorectal cancer patients BMC Cancer 9 88 10.1186/1471-2407-9-88 19302716
13. TG Allen-Mersh, et al. 2007 Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma Br J Surg 94 1 96 105 10.1002/bjs.5526 17058316
14. JL Gala, et al. 1998 Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization Clin Chem 44 3 472 481 9510850
15. MR Smith S Biggar M Hussain 1995 Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases Cancer Res 55 12 2640 2644 7540108
16. JA Lopez-Guerrero, et al. 1997 Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR) Clin Chim Acta 263 1 105 116 10.1016/S0009-8981(97)00054-5 9247732
17. B Molnar, et al. 2003 Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients Dig Dis 21 4 320 325 10.1159/000075355 14752222
18. B Molnar, et al. 2001 Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients Clin Cancer Res 7 12 4080 4085 11751505
19. TE Witzig, et al. 2002 Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy Clin Cancer Res 8 5 1085 1091 12006523
20. WJ Allard, et al. 2004 Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 20 6897 6904 10.1158/1078-0432.CCR-04-0378 15501967
21. SJ Cohen, et al. 2006 Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer Clin Colorectal Cancer 6 2 125 132 10.3816/CCC.2006.n.029 16945168
22. SJ Cohen, et al. 2008 Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 19 3213 3221 10.1200/JCO.2007.15. 8923 18591556
23. Groot M, et al.: Circulating tumor cells (CTC) in newly diagnosed breast or colorectal cancers. J Clin Oncol 2007, 25(18S: June 20 Suppl: abstr 14512)
24. K Hiraiwa, et al. 2008 Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers Ann Surg Oncol 15 11 3092 3100 10.1245/s10434-008-0122-9 18766405
25. J Sastre, et al. 2008 Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables Ann Oncol 19 5 935 938 10.1093/annonc/mdm583 18212090
26. M Cristofanilli, et al. 2004 Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 8 781 791 10.1056/NEJMoa040766 15317891
27. JG Moreno, et al. 2001 Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status Urology 58 3 386 392 10.1016/S0090-4295(01)01191-8 11549486
28. RT Krivacic, et al. 2004 A rare-cell detector for cancer Proc Natl Acad Sci USA 101 29 10501 10504 10.1073/pnas.0404036101 15249663
29. S Nagrath, et al. 2007 Isolation of rare circulating tumour cells in cancer patients by microchip technology Nature 450 7173 1235 1239 10.1038/nature06385 18097410
30. S Maheswaran, et al. 2008 Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 4 366 377 10.1056/NEJMoa0800668 18596266
31. Cohen SJ, et al.: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009, 20(7):1223-1229.
32. J Tol, et al. 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 6 563 572 10.1056/NEJMoa0808268 19196673
33. Koopman M, et al.: Circulating tumor cells (CTC) in advanced colorectal cancer (ACC) patients undergoing 1st line treatment with chemotherapy, bevacizumab and cetuximab as an important and early predictor of survival. Ann Oncol 2008, 19(suppl 8: viii 166)
34. SC Wong, et al. 2009 Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients Clin Cancer Res 15 3 1005 1012 10.1158/1078-0432. CCR-08-1515 19188172
35. Matsusaka S, et al.: Use of circulating tumor cells and circulating endothelial cells as surrogate markers for FOLFOX4 with or without bevacizumab in mCRC. ASCO Gastrointestinal Cancers Symp, 2009 (abstr 345)
36. H Hurwitz, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691 15175435
37. A Falcone, et al. 2007 Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 13 1670 1676 10.1200/JCO.2006.09.0928 17470860
38. Y Fong, et al. 1999 Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 3 309 318 10.1097/00000658-199909000-00004 10493478 discussion 318-321
39. http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf. Accessed March 11, 2009
40. B Nordlinger, et al. 2008 Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 9617 1007 1016 10.1016/S0140-6736(08)60455-9 18358928
41. T Andre, et al. 2004 Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 23 2343 2351 10.1056/NEJMoa032709 15175436
42. Wolmark N, et al.: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2009, 27(18 suppl; abstr LBA4)
43. Kerr D, et al.: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009, 27(15 suppl; abstr 4000)
44. JS de Bono, et al. 2007 Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor Clin Cancer Res 13 12 3611 3616 10.1158/1078-0432.CCR-07-0268 17575225
45. J Guo, et al. 2005 Detection of cytokeratin 20 mRNA in the peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymerase chain reaction J Gastroenterol Hepatol 20 8 1279 1284 10.1111/j.1440-1746.2005.03894.x 16048578
46. Lim HJ, et al.: EGFR staining of circulating tumor cells (CTCs) from patients with metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symp 2009 (abstr 373)
47. E Van Cutsem, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 10.1200/JCO.2006.08.1620 17470858
48. Hendlisz A, et al.: Modulation and prognostic value of epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) during chemotherapy (CT) in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(May 20 suppl; abstr 15038)